Our portfolio company, Phialogics – a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed financing round with HTGF (High-Tech Gründerfonds).
The fresh capital will be used to further develop Phialogics’ lead candidate in preclinical models in comparison to the current standard of care and other research approaches. Phialogics is one step closer to bringing new solutions to patients who are in need of better treatment options!
“We are excited to invest in the strong team of Phialogics and their innovative approach to modulate the immune response in inflammatory diseases. Their unique platform based on naturally occurring receptor-ligand interactions combined with a first class protein engineering expertise and deep knowledge in immunology has the potential to provide novel solutions for patients. We are excited to see the progress they will make with this pre-seed funding,” says Dr. Katharina Severin, Investment Manager at HTGF.
We are happy to see our portfolio companies growing and are looking forward to future developments!